# CONCORDE (NCT01348217)

> Radiochemotherapy With and Without Dose Escalation in Patients Presenting Locally Advanced or Inoperable Carcinoma of the Oesophagus

No report yet. It can be ordered.

- Indication: locally advanced or inoperable esophageal carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01348217
- Phase: PHASE2, PHASE3
- Status: COMPLETED
- Sponsor: Centre Georges Francois Leclerc
- Conditions: Esophageal Cancer
- Interventions: Conformal 3D Radiotherapy with " ENI "-type prophylactic irradiation of the lymph node; Boost; Boost; chemotherapy: FOLFOX 4
- Enrollment: 196
- Primary outcome: Evaluate the rate of acute toxicity leading to cessation or temporary interruption of treatment of more than a total of 14 days or of 7 consecutive days during the whole treatment.
- Primary outcome: Evaluate the rate of completes endoscopic response at 3 months
- Primary outcome: Survival without locoregional relapse at 2 years (time elapsed between date of randomisation and onset of local relapse and/or lymph node involvement)

## Indexed commentary on CONCORDE so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 75 posts on X
- 3 YouTube videos

## Order

Deep, $1,950 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=concorde-nct01348217

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01348217", "email": "<work email>"}; the inbox owner confirms by the emailed link.